{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:29:47Z","timestamp":1792085387876,"version":"4.4.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1097\/iop.0b013e3182831bf3","type":"journal-article","created":{"date-parts":[[2013,2,27]],"date-time":"2013-02-27T12:48:03Z","timestamp":1361969283000},"page":"87-92","source":"Crossref","is-referenced-by-count":79,"title":["Targeted Therapy for Orbital and Periocular Basal Cell Carcinoma and Squamous Cell Carcinoma"],"prefix":"10.1097","volume":"29","author":[{"given":"Vivian T.","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret L.","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Esmaeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210129","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1524-4725.2012.02367.x","article-title":"Periocular cutaneous malignancies: a review of the literature.","volume":"38","author":"Slutsky","year":"2012","journal-title":"Dermatol Surg"},{"key":"R2-3-20210129","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/1097-0142(197912)44:6<2294::AID-CNCR2820440644>3.0.CO;2-G","article-title":"The basal cell nevus syndrome: disasters occurring among a series of 36 patients.","volume":"44","author":"Southwick","year":"1979","journal-title":"Cancer"},{"key":"R5-3-20210129","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0140-6736(92)90868-4","article-title":"Location of gene for Gorlin syndrome.","volume":"339","author":"Farndon","year":"1992","journal-title":"Lancet"},{"key":"R6-3-20210129","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0092-8674(00)81268-4","article-title":"Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome.","volume":"85","author":"Hahn","year":"1996","journal-title":"Cell"},{"key":"R7-3-20210129","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1126\/science.272.5268.1668","article-title":"Human homolog of patched, a candidate gene for the basal cell nevus syndrome.","volume":"272","author":"Johnson","year":"1996","journal-title":"Science"},{"key":"R8-3-20210129","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/sj.onc.1208240","article-title":"Constitutive activation of the shh-ptc1 pathway by a patched1 mutation identified in BCC.","volume":"24","author":"Barnes","year":"2005","journal-title":"Oncogene"},{"key":"R9-3-20210129","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1101\/gad.938601","article-title":"Hedgehog signaling in animal development: paradigms and principles.","volume":"15","author":"Ingham","year":"2001","journal-title":"Genes Dev"},{"key":"R10-3-20210129","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0092-8674(00)81374-4","article-title":"Dual roles for patched in sequestering and transducing Hedgehog.","volume":"87","author":"Chen","year":"1996","journal-title":"Cell"},{"key":"R11-3-20210129","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/34201","article-title":"Activating Smoothened mutations in sporadic basal-cell carcinoma.","volume":"391","author":"Xie","year":"1998","journal-title":"Nature"},{"key":"R12-3-20210129","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1046\/j.1523-1747.2001.01315.x","article-title":"Activation of expression of hedgehog target genes in basal cell carcinomas.","volume":"116","author":"Bonifas","year":"2001","journal-title":"J Invest Dermatol"},{"key":"R13-3-20210129","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/417299a","article-title":"Hedgehog regulates cell growth and proliferation by inducing cyclin D and cyclin E.","volume":"417","author":"Duman-Scheel","year":"2002","journal-title":"Nature"},{"key":"R14-3-20210129","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/89083","article-title":"The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors.","volume":"7","author":"Pola","year":"2001","journal-title":"Nat Med"},{"key":"R15-3-20210129","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1016\/j.bmcl.2009.08.049","article-title":"GDC-0449-a potent inhibitor of the hedgehog pathway.","volume":"19","author":"Robarge","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"R16-3-20210129","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1200\/JCO.2010.27.9943","article-title":"Clinical experience with hedgehog pathway inhibitors.","volume":"28","author":"Low","year":"2010","journal-title":"J Clin Oncol"},{"key":"R17-3-20210129","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1039\/B910196A","article-title":"Small-molecule modulators of the Sonic Hedgehog signaling pathway.","volume":"6","author":"Stanton","year":"2010","journal-title":"Mol Biosyst"},{"key":"R18-3-20210129","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1158\/1078-0432.CCR-10-3370","article-title":"Targeting superficial or nodular Basal cell carcinoma with topically formulated small molecule inhibitor of smoothened.","volume":"17","author":"Tang","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R19-3-20210129","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1158\/1078-0432.CCR-10-2745","article-title":"Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.","volume":"17","author":"LoRusso","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R20-3-20210129","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1158\/1078-0432.CCR-11-0972","article-title":"Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors.","volume":"17","author":"Lorusso","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R21-3-20210129","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJMoa0905360","article-title":"Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.","volume":"361","author":"Von Hoff","year":"2009","journal-title":"N Engl J Med"},{"key":"R22-3-20210129","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma.","volume":"366","author":"Sekulic","year":"2012","journal-title":"N Engl J Med"},{"key":"R23-3-20210129","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/(SICI)1096-8628(19970331)69:3<299::AID-AJMG16>3.0.CO;2-M","article-title":"Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome.","volume":"69","author":"Kimonis","year":"1997","journal-title":"Am J Med Genet"},{"key":"R24-3-20210129","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1113538","article-title":"Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.","volume":"366","author":"Tang","year":"2012","journal-title":"N Engl J Med"},{"key":"R25-3-20210129","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network.","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R26-3-20210129","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1600-0560.2009.01316.x","article-title":"Epidermal growth factor receptor (EGFR) expression in periocular and extraocular sebaceous carcinoma.","volume":"37","author":"Ivan","year":"2010","journal-title":"J Cutan Pathol"},{"key":"R27-3-20210129","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.prp.2011.03.002","article-title":"Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.","volume":"207","author":"Uribe","year":"2011","journal-title":"Pathol Res Pract"},{"issue":"2B","key":"R28-3-20210129","first-page":"1205","article-title":"Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin.","volume":"25","author":"Maubec","year":"2005","journal-title":"Anticancer Res"},{"key":"R29-3-20210129","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.humpath.2007.07.004","article-title":"Epidermal growth factor receptor: a novel biomarker for aggressive head and neck cutaneous squamous cell carcinoma.","volume":"39","author":"Chng","year":"2008","journal-title":"Hum Pathol"},{"key":"R30-3-20210129","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000051637","article-title":"Epidermal growth factor receptor overexpression and genetic aberrations in metastatic squamous-cell carcinoma of the skin.","volume":"202","author":"Shimizu","year":"2001","journal-title":"Dermatology (Basel)"},{"key":"R31-3-20210129","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/01.iop.0000202609.92772.c3","article-title":"Expression of the epidermal growth factor receptor in conjunctival squamous cell carcinoma.","volume":"22","author":"Shepler","year":"2006","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"R32-3-20210129","first-page":"4322","article-title":"Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.","volume":"53","author":"Fan","year":"1993","journal-title":"Cancer Res"},{"key":"R33-3-20210129","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1200\/JCO.2010.34.1735","article-title":"Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.","volume":"29","author":"Maubec","year":"2011","journal-title":"J Clin Oncol"},{"key":"R34-3-20210129","first-page":"5749","article-title":"ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.","volume":"62","author":"Wakeling","year":"2002","journal-title":"Cancer Res"},{"key":"R35-3-20210129","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1158\/1078-0432.CCR-11-1951","article-title":"A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck.","volume":"18","author":"Lewis","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R36-3-20210129","first-page":"4838","article-title":"Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.","volume":"57","author":"Moyer","year":"1997","journal-title":"Cancer Res"},{"key":"R37-3-20210129","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1097\/JTO.0b013e3181f1c7b0","article-title":"Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.","volume":"5","author":"Reck","year":"2010","journal-title":"J Thorac Oncol"},{"key":"R38-3-20210129","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1200\/JCO.2001.19.13.3267","article-title":"Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.","volume":"19","author":"Hidalgo","year":"2001","journal-title":"J Clin Oncol"},{"key":"R39-3-20210129","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/IOP.0b013e31802d9802","article-title":"Erlotinib-associated trichomegaly.","volume":"23","author":"Lane","year":"2007","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"R40-3-20210129","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-4632.2009.03752.x","article-title":"A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva).","volume":"48","author":"Marquez","year":"2009","journal-title":"Int J Dermatol"},{"key":"R41-3-20210129","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/IOP.0b013e31802d97f0","article-title":"Newly recognized ocular side effects of erlotinib.","volume":"23","author":"Methvin","year":"2007","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"R42-3-20210129","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jaad.2009.12.042","article-title":"Metastatic cutaneous squamous cell carcinoma responding to erlotinib therapy.","volume":"65","author":"Engelhardt","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"R43-3-20210129","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1200\/jco.2007.25.18_suppl.16519","article-title":"Squamous carcinoma of the skin responding to erlotinib: three cases.","volume":"25","author":"Read","year":"2007","journal-title":"J Clin Oncol"},{"key":"R44-3-20210129","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1001\/archophthalmol.2012.2515","article-title":"Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma.","volume":"130","author":"El-Sawy","year":"2012","journal-title":"Arch Ophthalmol"}],"container-title":["Ophthalmic Plastic &amp; Reconstructive Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IOP.0b013e3182831bf3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:52:52Z","timestamp":1620957172000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002341-201303000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/iop.0b013e3182831bf3","relation":{},"ISSN":["0740-9303"],"issn-type":[{"value":"0740-9303","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}